These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9215602)

  • 61. Synthetic Strategies Employed for the Construction of Fostriecin and Related Natural Products.
    Trost BM; Knopf JD; Brindle CS
    Chem Rev; 2016 Dec; 116(24):15035-15088. PubMed ID: 28027648
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Viewing serine/threonine protein phosphatases through the eyes of drug designers.
    Zhang M; Yogesha SD; Mayfield JE; Gill GN; Zhang Y
    FEBS J; 2013 Oct; 280(19):4739-60. PubMed ID: 23937612
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death.
    Theobald B; Bonness K; Musiyenko A; Andrews JF; Urban G; Huang X; Dean NM; Honkanen RE
    Mol Cancer Res; 2013 Aug; 11(8):845-55. PubMed ID: 23671329
    [TBL] [Abstract][Full Text] [Related]  

  • 64. De novo synthesis of natural products via the asymmetric hydration of polyenes.
    Wang Y; Xing Y; Zhang Q; O'Doherty GA
    Chem Commun (Camb); 2011 Aug; 47(30):8493-505. PubMed ID: 21559534
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Total synthesis of fostriecin: via a regio- and stereoselective polyene hydration, oxidation, and hydroboration sequence.
    Gao D; O'Doherty GA
    Org Lett; 2010 Sep; 12(17):3752-5. PubMed ID: 20687585
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors.
    Swingle MR; Amable L; Lawhorn BG; Buck SB; Burke CP; Ratti P; Fischer KL; Boger DL; Honkanen RE
    J Pharmacol Exp Ther; 2009 Oct; 331(1):45-53. PubMed ID: 19592665
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Protein phosphatase 2A enhances activation of human immunodeficiency virus type 1 by phorbol myristate acetate.
    Faulkner NE; Lane BR; Bock PJ; Markovitz DM
    J Virol; 2003 Feb; 77(3):2276-81. PubMed ID: 12525665
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity.
    Cheng A; Balczon R; Zuo Z; Koons JS; Walsh AH; Honkanen RE
    Cancer Res; 1998 Aug; 58(16):3611-9. PubMed ID: 9721869
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A.
    Roberge M; Tudan C; Hung SM; Harder KW; Jirik FR; Anderson H
    Cancer Res; 1994 Dec; 54(23):6115-21. PubMed ID: 7954457
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
    de Jong S; Zijlstra JG; Mulder NH; de Vries EG
    Cancer Chemother Pharmacol; 1991; 28(6):461-4. PubMed ID: 1657425
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
    de Jong RS; Mulder NH; Uges DR; Sleijfer DT; Höppener FJ; Groen HJ; Willemse PH; van der Graaf WT; de Vries EG
    Br J Cancer; 1999 Feb; 79(5-6):882-7. PubMed ID: 10070885
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fostriecin: a review of the preclinical data.
    de Jong RS; de Vries EG; Mulder NH
    Anticancer Drugs; 1997 Jun; 8(5):413-8. PubMed ID: 9215602
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Fostriecin: chemistry and biology.
    Lewy DS; Gauss CM; Soenen DR; Boger DL
    Curr Med Chem; 2002 Nov; 9(22):2005-32. PubMed ID: 12369868
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
    Valkov NI; Sullivan DM
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.